



CHF Solutions, Inc. Launches Enhanced Educational Materials to Expand Utilization of the Aquadex FlexFlow System

March 19, 2018

EDEN PRAIRIE, Minn., March 19, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today the launch of a suite of new educational and sales support materials designed to expand utilization of the company's Aquadex FlexFlow system and enhance the user experience when performing ultrafiltration therapy.

The cornerstone of this new literature is the "Quick Start Guide," which provides comprehensive instruction on delivering ultrafiltration therapy, and troubleshooting technical issues. CHF Solutions sales staff will also be equipped with advanced sales collateral that incorporate the latest clinical data on ultrafiltration therapy for heart failure patients with fluid overload, as well as a recent case study.

"We are passionately committed to serving our current and growing customer base by supporting their use of the Aquadex FlexFlow system, thereby enhancing the customer experience and creating a clearer path toward expanded utilization for heart failure patients with fluid overload," said Jim Breidenstein, chief commercial officer of CHF Solutions. "These materials have been developed over the last several months, incorporating clear instruction, the latest clinical data, and an easy-to-navigate design, in order to meet this goal. We look forward to providing best in class service and support as we assist patients in need of an alternative therapy to intravenous diuretics."

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

[Primary Logo](#)

Source: CHF Solutions, Inc.